Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is an outpatient, single center, between-group, double blind, placebo controlled design.
Approximately 120 adolescents and adult patients will be randomized to either have their
treatment augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8
weeks. The study will examine CBD as an augmentation strategy in early psychosis. It is
hypothesized that CBD will improve symptoms, neurocognition, markers of inflammation and
eating behaviors. Importantly, moderators and mediators of the CBD effects will be explored.